The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial program

American Journal of Cardiology

Volumn 91, Issue 10 SUPPL. 1, 2003, Pages 28-34

  Unger, Thomas ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DEMENTIA; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; REVIEW; SIDE EFFECT; STROKE;

EID: 0038777134     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00230-3     Document Type: Review

References (52)

1. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol. 89:(suppl):2002;11A-16A ; discussion 16A-17A.
2. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure Collaborative Group on ACE Inhibitor Trials . JAMA. 273:1995;1450-1456.
3. Cleland J.G., Erhardt L., Murray G., Hall A.S., Ball S.G. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure a report from the AIRE Study Investigators . Eur Heart J. 18:1997;41-51.
4. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., Konstam M.A., Riegger G., Klinger G.H., Neaton J., Sharma D., Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomised trial: the Losartan Heart Failure Survival Study ELITE II . Lancet. 355:2000;1582-1587.
5. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moye L., Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction a systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group . Lancet. 355:2000;1575-1581.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
7. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,015 individuals with previous stroke or transient ischaemic attack. Lancet. 358:2001;1033-1041.
8. Alderman C.P. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother. 30:1996;55-61.
9. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet. 355:2000;637-645.
10. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675.
11. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor agonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
12. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
13. Parving H.-H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878.
14. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., Diez J., Drexler H., Ferrari R., Van Gilst W., et al. Pathophysiologic and therapeutic importance of tissue ACE a consensus report . Cardiovasc Drugs Ther. 16:2002;149-160.
15. Urata H., Nishimura H., Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens. 9:1996;277-284.
16. Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J. 139:2000;S2-S8.
17. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 89:(suppl):2002;3A-9A.
18. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation contribution to alterations of vasomotor tone . J Clin Invest. 97:1996;1916-1923.
19. Scheidegger K.J., Butler S., Witztum J.L. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem. 272:1997;21609-21615.
20. Yanagitani Y., Rakugi H., Okamura A., Moriguchi K., Takiuchi S., Ohishi M., Suzuki K., Higaki J., Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 33:1999;335-339.
21. Kintscher U., Wakino S., Kim S., Fleck E., Hsueh W.A., Law R.E. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension. 37:2001;587-593.
22. Grafe M., Auch-Schwelk W., Zakrzewicz A., Regitz-Zagrosek V., Bartsch P., Graf K., Loebe M., Gaehtgens P., Fleck E. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 81:1997;804-811.
23. Dol F., Martin G., Staels B., Mares A.M., Cazaubon C., Nisato D., Bidouard J.P., Janiak P., Schaeffer P., Herbert J.M. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 38:2001;395-405.
24. Figueroa J.E., Vijayagopal P. Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis. 162:2002;261-268.
25. Medina R., Cardona-Sanclemente L.E., Born G.V., Brown M.J. Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats. J Cardiovasc Pharmacol. 29:1997;125-129.
26. Oubina M.P., de Las Heras N., Vazquez-Perez S., Cediel E., Sanz-Rosa D., Ruilope L.M., Cachofeiro V., Lahera V. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens. 20:2002;303-310.
27. Napoleone E., Di Santo A., Camera M., Tremoli E., Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res. 86:2000;139-143.
28. Buczko W., Matys T., Pawlak R., Kucharewicz I., Chabielska E. Studies on the antithrombotic action of AT1 receptor antagonists. Med Sci Monit. 7:2001;600-605.
29. Strehlow K., Wassmann S., Bohm M., Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med. 32:2000;386-389.
30. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 100:1999;2131-2134.
31. Smith D.H., Matzek K.M., Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 40:2000;1380-1390.
32. Neutel J.M., Frishman W.H., Oparil S., Papademitriou V., Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 6:1999;161-166.
33. Lacourcière Y., Lenis J., Orchard R., Lewanczuk R., Houde M., Pesant Y., Wright J., Wilson T., Martin K. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit. 3:1998;295-302.
34. Freytag F, Schelling A, Meinicke T, Deichsel G. Telmisartan Hypertension Experience in a Randomized European Study versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001;23:108-123.
35. Lacourcière Y. The incidence of cough a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist: Telmisartan Cough Study Group . Int J Clin Pract. 53:1999;99-103.
36. McClellan K.J., Markham A. Telmisartan. Drugs. 56:1998;1039-1044.
37. Mallion J., Siche J., Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 13:1999;657-664.
38. Littlejohn T., Mroczek W., Marbury T., VanderMaelen C.P., Dubiel R.F. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 16:2000;1123-1132.
39. Muller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler C.A., Parker C., Poole W.K., Passamani E., Roberts R., Robertson T., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 313:1985;1315-1322.
40. Cohen M.C., Rohtla K.M., Lavery C.E., Muller J.E., Mittleman M.A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol. 79:1997;1512-1516.
41. Willich S.N., Levy D., Rocco M.B., Tofler G.H., Stone P.H., Muller J.E. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol. 60:1987;801-806.
42. Willich S.N., Goldberg R.J., Maclure M., Perriello L., Muller J.E. Increased onset of sudden cardiac death in the first three hours after awakening. Am J Cardiol. 70:1992;65-68.
43. Marler Jr, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, Hier DB, Wolf PA, Caplan LR, Foulkes MA. Morning increase in onset of ischemic stroke. Stroke 1989;20:473-476.
44. Lago A., Geffner D., Tembl J., Landete L., Valero C., Baquero M. Circadian variation in acute ischemic stroke a hospital-based study . Stroke. 29:1998;1873-1875.
45. Weber M.A. The 24-hour blood pressure pattern does it have implications for morbidity and mortality? Am J Cardiol. 89:(suppl):2002;27A-33A.
46. Verdecchia P. Prognostic value of ambulatory blood pressure current evidence and clinical implications . Hypertension. 35:2000;844-851.
47. Warner G.T., Perry C.M. Ramipril a review of its use in the prevention of cardiovascular outcomes . Drugs. 62:2002;1381-1405.
48. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) . Circulation. 103:2001;919-925.
49. Dagenais G.R., Yusuf S., Bourassa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., Grover J. Effects of ramipril on coronary events in high-risk persons results of the Heart Outcomes Prevention Evaluation study . Circulation. 104:2001;522-526.
50. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., Bosch J., Sussex B., Probstfield J., Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621.
51. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy . Lancet. 355:2000;253-259.
52. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., Tsuyuki R.T., White M., Rouleau J., Latini R., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators . Circulation. 100:1999;1056-1064.